A PIONEERING COMPANY OF FIRSTS
HIGH PARK COMPANY LAUNCHES
Tilray launches High Park Company, a wholly-owned subsidiary to capture Canada’s adult-use cannabis market. Based in Toronto and led by a team with deep experience in cannabis and global consumer brands, High Park has secured the exclusive rights to produce and distribute a broad-based portfolio of adult-use cannabis brands and products in Canada. The company also announced that it is making an investment of up to $10 million in a new facility located in London, Ontario to process and distribute finished cannabis products.
TILRAY SIGNS SUPPLIER AGREEMENT WITH PHARMASAVE
Tilray announces that it has entered into an agreement to become a preferred medical cannabis supplier to Pharmasave, the premier independent pharmacy banner in Canada.
TILRAY FORMS ALLIANCE WITH SANDOZ
Tilray becomes the world’s first federally licensed medical cannabis producer to form a strategic alliance with a local affiliate of a global pharmaceutical company with a binding letter of intent (LOI) to be the exclusive collaborator of Sandoz Canada, part of the Novartis Group.
TILRAY EXPORTS TO SOUTH AFRICA
Africa becomes the fifth continent where Tilray products are available.
TILRAY CLOSES SERIES A
Tilray announces the completion of a C$60 million Series A funding round led by global institutional investors. The round marks the first time that outside investors have invested directly into a Privateer Holdings portfolio company. With its Series A funding and incorporation, Tilray is positioned to operate and finance its growth independent of Privateer Holdings.
TILRAY SIGNS SUPPLIER AGREEMENT WITH SHOPPERS DRUG MART
Tilray announces that it has entered into an agreement to become a medical cannabis supplier to Shoppers Drug Mart, one of Canada’s largest pharmacy chains.
PRIVATEER CLOSES SERIES C, ANNOUNCES EQUITY PLEDGE
Privateer Holdings closes its Series C funding round. The more than $100 million in new funding brings the firm’s fundraising total to $200 million, the largest private capital raise closed in the legal cannabis industry to date. In addition to announcing the close of the round, Privateer Holdings founders Brendan Kennedy, Michael Blue and Christian Groh pledge to donate shares of their personal holdings in the firm to support communities that have been harmed by cannabis prohibition worldwide. Currently equivalent to $5 million, the value of the equity pledged will grow over time with the value of the firm.
TILRAY EXPORTS TO THE CZECH REPUBLIC
The Czech Republic becomes the fourth EU country with Tilray products available to patients.
PRIVATEER HOLDINGS AQUIRES THE GOODSHIP
The Goodship, one of Washington state’s leading edibles brands, joins the Privateer Holdings portfolio. Together, The Goodship and Privateer Holdings plan to develop new products and expand the brand’s availability to consumers in new markets across North America.
LEAFLY PUBLISHES FIRST BOOK
“A weirdly fascinating volume … [on] a new kind of cultivated landscape that may soon stretch from sea to shining sea.” —The New York Times Book Review
Find The Leafly Guide to Cannabis online or at a bookseller near you.
TILRAY EXPORTS GENETICS TO PORTUGAL
Tilray successfully exports live medical cannabis genetics from its flagship British Columbia, Canada facility to its European Union Campus in Cantanhede, Portugal. The announcement is the first time a company has legally exported live cannabis genetics from North America to Europe and marks another strategic milestone as Tilray develops its EU Campus into the region’s leading medical cannabis research and production facility.
TILRAY EXPORTS TO GERMANY
Tilray becomes the first Canadian licensed producer to legally import full-spectrum medical cannabis extract products into Germany for nationwide distribution through pharmacies. To distribute its products nationwide, Tilray has partnered with pharmaceutical wholesaler NOWEDA and service provider Paesel + Lorei. With more than €6 billion in annual revenue, NOWEDA is one of the largest pharmaceutical wholesalers in Germany.
TILRAY ANNOUNCES EU CAMPUS
Tilray receives a license to produce medical cannabis in the European Union, becoming the first licensed producer with federal cultivation licenses from two countries. The company will invest up to €20 million in a European Union Campus in Cantanhede, Portugal.
TILRAY ANNOUNCES SECOND FACILITY
Tilray Announces Second Facility
MARLEY NATURAL'S EUROPEAN DEBUT AT COLETTE
Marley Natural at Colette
TILRAY MEDICAL ADVISORY BOARD
Tilray Medical Advisory Board
MARLEY NATURAL EXPANDS TO WASHINGTON
Marley Natural Expands to Washington
TILRAY ANNOUNCES PEDIATRIC EPILEPSY
Tilray announces its support for a clinical trial at The Hospital for Sick Children in Toronto (SickKids) to study medical cannabis extracts and treatment-resistant epilepsy in children. The trial, which uses preparations developed by Tilray, receives coverage from The Canadian Press.
LEAFLY SURPASSES 10 MILLION UNIQUE VISITORS PER MONTH
Monthly traffic exceeds that of many popular non-cannabis websites, including
The Atlantic, Financial Times, and New York Magazine.
PRIVATEER HOLDINGS CLOSES $40M IN CONVERTIBLE BRIDGE FINANCING
TILRAY BEGINS PATIENT RECRUITMENT FOR
The clinical trial, which uses a Tilray study drug, is the largest medical cannabis clinical trial to take place in Canada in the last 40 years. The Vancouver Sun covers
TILRAY EXPANDS TO THIRD CONTINENT
Tilray begins exporting to Australia for compassionate access and clinical
MARLEY NATURAL RISE UP EXPUNGEMENT DAY
Marley Natural partners with the Minority Cannabis Business Association to host Rise Up Expungement Day. Dozens of people with criminal records for non-violent cannabis-related offenses have the opportunity to file official expungement requests with the State of Oregon. USA TODAY covers the news.
TILRAY BEGINS EXPORTING CANNABIS INTERNATIONALLY
In June, Tilray made history when it became the first company to legally ship medical cannabis products from North America to the European Union. Tilray's liquid cannabis capsules are now being distributed in pharmacies across Croatia. Read more about this historic milestone in CBC News.
ANNOUNCED AUSTRALIAN CLINICAL RESEARCH PARTNERSHIP
Tilray partners with the University of Sydney, New South Wales Government, and Chris O'Brien Lifehouse (one of Australia's leading cancer hospitals) to conduct a first-of-its-kind clinical trial studying how cannabinoids can benefit patients with chemotherapy-induced nausea and vomiting (CINV).